Featured Research

from universities, journals, and other organizations

Use of 17-hydroxyprogesterone doesn't reduce rate of preterm delivery or complications in twins, study suggests

Date:
February 10, 2011
Source:
Society for Maternal-Fetal Medicine
Summary:
The use of the hormone 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins, study suggests.

In a study to be presented February 10 at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will present findings that show that the use of the hormone 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins.

Related Articles


The hormone 17-Hydroxyprogesterone is sometimes used to reduce the risk of preterm labor. In 2008, the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine issued an opinion that further studies were needed and that "based on current knowledge, it is important to offer progesterone for pregnancy prolongation to only women with a documented history of a previous spontaneous birth at less than 37 weeks of gestation."

"We chose to study the effects of progesterone on twin pregnancies since that group is at a high risk of preterm delivery and we are always looking for something that will reduce those risks," said C. Andrew Combs, M.D., one of the study's authors.

Combs and his colleagues conducted a placebo-controlled, double-blind, multicenter, randomized clinical trial. Mothers with diamnioticdichorionic twins were randomized to 17-alpha-hydroxyxprogesterone caproate (17P) (250 mg IM) or placebo (castor oil vehicle, 1 mL), starting at 16-23 weeks gestational age (GA), repeated weekly until 34 weeks GA. A sample size of 240 mothers (480 babies) was calculated to give 80% power to detect reduction of composite neonatal morbidity from 45% with placebo to 30% with 17P.

One hundred and sixty mothers were randomized to 17P, 80 to placebo at mean GA of 20 weeks. The results showed that Baseline characteristics were similar between the groups. There was no significant difference in composite neonatal morbidity (14% with 17P vs. 12% with placebo), or in mean GA at delivery (35.3 wks vs. 35.9 wks), delivery < 28 wks (2% vs. 1%), < 32 wks (9% vs. 5%), < 35 wks (33% vs. 26%). There were no perinatal deaths in the 17P group and three neonatal deaths in the placebo group, two after withdrawal of life support because of fetal anomalies not discovered prenatally and one attributed to neonatal sepsis.

The study concludes that the use of 17P in twin pregnancies did not reduce the rate of preterm delivery or neonatal morbidity.

"We also noted that contrary to our previous study that showed an increased risk of pregnancy loss in triplet pregnancies treated with 17P, we had no deaths in the twins treated with 17P," said Combs. "However more studies are needed and it is clear that 17P should only be used with specific high risk pregnancy groups."


Story Source:

The above story is based on materials provided by Society for Maternal-Fetal Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Maternal-Fetal Medicine. "Use of 17-hydroxyprogesterone doesn't reduce rate of preterm delivery or complications in twins, study suggests." ScienceDaily. ScienceDaily, 10 February 2011. <www.sciencedaily.com/releases/2011/02/110210080231.htm>.
Society for Maternal-Fetal Medicine. (2011, February 10). Use of 17-hydroxyprogesterone doesn't reduce rate of preterm delivery or complications in twins, study suggests. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2011/02/110210080231.htm
Society for Maternal-Fetal Medicine. "Use of 17-hydroxyprogesterone doesn't reduce rate of preterm delivery or complications in twins, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/02/110210080231.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins